Ion Flux and Ligand Binding Assays for Analysis of Ion Channels

Expression and Analysis of Recombinant Ion Channels: From Structural Studies to Pharmacological Screening

Volumn , Issue , 2006, Pages 165-186

  Terstappen, Georg C ^a  

^a Siena Biotech SpA   (Italy)

Author keywords

Analysis of ion channels; Expression of recombinant ion channels; Heterogeneous binding assays; Homogeneous binding assays; Ion flux assays; Ligand binding assays; Nonradioactive ion flux assays; Radioactive ion flux assays

Indexed keywords

EID: 84889783123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608095.ch7     Document Type: Chapter

References (75)

1. J. C. Venter et al., The sequence of the human genome, Science 2001, 291, 1304-1351.
2. G. C. Terstappen, Ion channel screening technologies today, Drug Discovery Today: Technologies 2005, 2, 133-140.
3. C. Virginio, A. Giacometti, L. Aldegheri, J. M. Rimland, G. C. Terstappen, Pharmacological properties of rat alpha7 nicotinic receptors expressed in native and recombinant cell systems, Eur. J. Pharmacol. 2002, 445, 153-161.
4. M. Willow, E. A. Kuenzel, Catterall, Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine, Mol. Pharm. 1984, 25, 228-234.
5. C. A. Rasmussen, J. L. Sutko,W. H. Barry. Effects of ryanodine and caffeine on contractility, membrane voltage, and calcium exchange in cultured heart cells, Circ Res. 1987, 60, 495-504.
6. K. G. Thampy, E. M. Barnes Jr., Gamma-aminobutyric acid-gated chloride channels in cultured cerebral neurons, J. Biol. Chem. 1984, 259, 1753-1757.
7. S. W. Weir, A. H. Weston, The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels, Brit. J. Pharmacol. 1986, 88, 121-128.
8. J. Denyer, J. Worley, B. Cox, G. Allenby, M Banks, HTS approaches to voltage-gated ion channel drug discovery, Drug Discovery Today 1998, 3, 323-332.
9. A. Cushing, M. J. Price-Jones, R. Graves, A. J. Harris, K. T. Hughes, D. Bleakman, D. Lodge, Measurement of calcium flux through ionotropic glutamate receptors using Cytostar-T scintillating microplates, J. Neurosci. Methods 1999, 90, 33-36.
10. J. W. Ford, E. B. Stevens, J. M. Treherne, J. Packer, M. Bushfield, Potassium channels: gene family, therapeutic relevance, high-throughput References 183 screening technologies and drug discovery, Prog. Drug Res. 2002, 58, 133-68.
11. G. C. Terstappen, Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay, Anal. Biochem. 1999, 272, 149-155.
12. B. Hille, Ionic Channels of Excitable Membranes, Sinauer Associates, Sunderland, MA, 1992
13. J-H. Zhang,T. D. Y. Chung, K. R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays, J. Biomol. Screen. 1999, 4, 67-73.
14. M. Garcia-Calvo, H-G. Knaus, O. B. McManus, K. M. Giangiacomo, G. Kaczorowski, M. L. Garcia, Purification and reconstitution of the highconductance, calcium-activated potassium channel from tracheal smooth muscle, J. Biol. Chem. 1994, 269, 676-682.
15. V. K. Gribkoff, et al., Effects of channel modulators on cloned large-conductance calcium-activated potassium channels, Mol. Pharmacol. 1996, 50, 206-217.
16. A. S. Parihar, D. R. Groebe,V. E. Scott, J. Feng, X-F. Zhang, U. Warrior, M. Gopalakrishnan, C-C. Shieh, Functional analysis of large conductance Ca2+ activated K+ channels: ion flux studies by atomic absorption spectrometry, Assay Drug Dev. Technol. 2003, 1, 647-654.
17. M. Kohler, B. Hirschberg, C. T. Bond, J. M. Kinzie, N. V. Marrion., J. Maylie, J. P. Adelman, Small-conductance Ca2+ activated K+ channels from mammalian brain, Science 1996, 273, 1709-1714.
18. X. M. Xia, et al., Mechanism of Ca2+ gating in small conductance Ca2+-activated K+ channels, Nature 1998, 395, 503-507.
19. G. C. Terstappen, A. Pellacani, L. Aldegheri, F. Graziani, C. Carignani, G. Pula, C. Virginio, The antidepressant fluoxetine blocks the human small conductance calciumactivated potassium channels SK1, SK2 and SK3, Neuroscience Lett. 2003, 346, 85-88.
20. C. W. Scott, D. E. Wilkins, S. Trivedi, D. J. Crankshaw, A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectroscopy, Anal. Biochem. 2003, 319, 251-257.
21. K. Wang, et al.,Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the Ion Channel Reader 8000, Assay Drug Dev. Technol. 2004, 2, 525-534.
22. J. I. Vandenberg, B. W. Walker,T. J. Campbell, HERK K+ channels: friend and foe. Trends Pharmacol. Sci. 2001, 22, 240-246.
23. W. Tang, J. Kang, X. Wu, D. Rampe, L. Wang, H. Shen, Z. Li, D. Dunnington, T. Garyantes, Development and evaluation of high throughput functional assay methods for hERG potassium channel, J. Biomol. Screen. 2001, 6, 325-331.
24. L. Stankovich, D. Wicks, S. Despotovski, D. Liang, Atomic absorption spectroscopy in ion channel screening, Assay Drug Dev. Technol. 2004, 2, 569-574.
25. G. C. Terstappen, Nonradioactive Rb+ efflux assay and its applications in drug discovery and development, Assay Drug Dev. Technol. 2004, 2, 553-559.
26. W. A. Catterall,V. Trainer, D. G. Baden, Molecular properties of the sodium channel: a receptor for multiple neurotoxins, Bull. Soc. Path. Exp. 1992, 85, 481-485.
27. J. L. Challinor-Rogers, D. C. Kong, M. N. Iskander, G. A. McPherson, Structure-activity relationship of glibenclamide analogs: A comparison of potency as levcromakalim antagonists in rat aorta vs. affinity for [3H]-glibenclamide binding to membranes from rat cerebral cortex, J. Pharmacol. Exp. Ther. 1995, 273, 778-86.
28. K. Finlayson, L. Turnbull, C. T. January, J. Sharkey, J. S. Kelly, [3H]-Dofetilide binding to HERK in transfected membranes: A potential high throughput preclinical screen, Eur. J. Pharmacol. 2001, 430, 147-148.
29. D. B. Bylund, M. L. Toews, Radioligand binding methods: practical guide and tips, Am. J. Physiol. 1993, 265, L421-429.
30. R. Cheng, G. Prusoff, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol. 1973, 22, 3099-4006.
31. N. D. Cook, Scintillation proximity assay: a versatile high-throughput screening technology, Drug Discovery Today 1996, 1, 287-294.
32. F. Graziani, A. Aldegheri, G. C. Terstappen, High throughput scintillation proximity assay for the identification of FKBP-12 ligands, J. Biomol. Screen. 1999, 4, 3-7.
33. W. B. Dandliker,V. A. de Saussure, Fluorescence polarization in immunochemistry, Immunochemistry 1970, 7, 799-828.
34. P. Perrin, Polarisation De La Lumière de fluorescence, J. Phys. Radium 1926, 7, 390-401.
35. M. Allen, J. Reeves, G. Mellor, High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors, J. Biomol. Screen. 2000, 5, 63-69.
36. P. Wu, M. Brasseur,W. Schindler, A high throughput STAT binding assay using fluorescence polarization, Anal. Biochem. 1997, 249, 29-36.
37. H. Glossmann, J. Striessnig, Molecular properties of calcium channels, Rev. Physiol. Biochem. Pharmacol. 1990, 114, 1-105.
38. A. Koschak, D. Reimer, I. Huber, M. Grabner, H. Glossmann, J. Engel, J. Striessnig, Cav1.3 subunits can form L-type calcium channels activating at negative voltages, J. Biol. Chem. 2001, 276, 22100-22106.
39. M. Hagiwara, S. Adachi-Akahne, T. Nagao, High-affinity binding of [3H]-DTZ323 to the diltiazem-binding site of L-type Ca2+ channels, Eur. J. Pharmacol. 2003, 466, 63-71.
40. M. E. Williams, et al., Structure and functional expression of an conotoxin-sensitive human N-type calcium channel, Science 1992, 257, 389-395.
41. P. Favreau, et al., A new omega-conotoxin that targets N-type voltage-sensitive calcium channels with unusual specificity, Biochemistry 2001, 40, 14567-14575.
42. R. J. Lewis, et al., Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes, J. Biol. Chem. 2000, 275, 35335-35344.
43. J. W. West,T. Scheuer, L. Maechler, W. A. Catterall, Efficient expression of rat brain type IIA Na+ channel subunits in a somatic cell line, Neuron 1992, 8, 59-70.
44. J. C. Rogers,Y. Qu,T. N. Tanada, T. Scheuer,W. A. Catterall, Molecular determinants of high affinity binding of ù-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel subunit, J. Biol. Chem. 1996, 271, 15950-15962.
45. S. Cestèle,Y. Qu, J. C. Rogers, H. Rochat,T. Scheuer,W. A. Catterall, Voltage sensor-trapping: enhanced activation of sodium channels by scorpion toxin bound to the S3-S4 loop in domain II, Neuron 1998, 21, 919-931.
46. R. S. Sheldon, N. J. Cannon, H. J. Duff, Binding of [3H]-batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels, Mol. Pharmacol. 1986, 30, 617-623.
47. M. Taouis, R. S. Sheldon, R. J. Hill, H. J. Duff, Cyclic AMP-dependent regulation of the number of [3H]-batrachotoxinin benzoate binding sites on rat cardiac myocytes, J. Biol. Chem. 1991, 266, 10300-10304.
48. A. J. Bourdelais, S. Campbell, H. Jacocks, J. Naar, J. L. Wright, J. Carsi, D. G. Baden, Brevenal is a natural inhibitor of brevetoxin action in sodium channel receptor binding assays, Cell. Mol. Neurobiol. 2004, 24, 553-63.
49. M. Yotsu-Yamashita, K. Nishimori, Y. Nitanai, M. Isemura, A. Sugimoto, T. Yasumoto, Binding properties of [3H]-PbTx-3 and [3H]-saxitoxin to brain membranes and to skeletal muscle References 185 membranes of puffer fish Fugu pardalis and the primary structure of a voltagegated Na+ channel alpha-subunit (fMNa1) from skeletal muscle of F. pardalis, Biochem. Biophys. Res. Commun., 2000, 267, 403-412.
50. O. Shamotienko, S. Akhtar, C. Sidera, F. A. Meunier, B. Ink, M. Weir, J. O. Dolly, Recreation of neuronal Kv1 channel oligomers by expression in mammalian cells using Semliki Forest virus, Biochemistry 1999, 38, 16766-16776.
51. J. Racape, A. Lecoq, R. Romi-Lebrun, J. Liu, M. Kohler, M. L. Garcia, A. Menez, S. Gasparini, Characterization of a novel radiolabeled peptide selective for a subpopulation of voltagegated potassium channels in mammalian brain, J. Biol. Chem. 2002, 277, 3886-3893.
52. P. J. Chiu, et al.,Validation of a [3H]-astemizole binding assay in HEK293 cells expressing HERG K+ channels, J. Pharmacol. Sci. 2004, 95, 311-319.
53. K. Finlayson, A. J. Pennington, J. S. Kelly, [3H]-dofetilide binding in SHSY5Yand HEK293 cells expressing a HERG-like K+ channel, Eur. J. Pharmacol. 2001, 412, 203-212.
54. R. Davis-Taber, et al., [125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: characterization and pharmacology of binding, Mol. Pharmacol. 2003, 64, 143-153.
55. P. W. Manley, C. Loffler-Walz, U. Russ, A. Hambrock,T. Moenius, U. Quast, Synthesis and characterization of a novel tritiated KATP channel opener with a benzopyran structure, Br. J. Pharmacol. 2001,133, 275-85.
56. M. Hanner, R. Vianna-Jorge, A. Kamassah.,W. A. Schmalhofer, H. G. Knaus, G. J. Kaczorowski, M. L. Garcia, The beta subunit of the high conductance calcium-activated potassium channel. Identification of residues involved in charybdotoxin binding, J. Biol. Chem. 1998, 273, 16289-16296.
57. A. Koschak, R. O. Koch, J. Liu, G. J. Kaczorowski, P. H. Reinhart, M. L. Garcia, H. G. Knaus, [125I]-Iberiotoxin-D19Y/Y36F, the first selective, high specific activity radioligand for high-conductance calcium-activated potassium channels, Biochemistry 1997, 36, 1943-1952.
58. D. O. Kiesewetter, E. M. Jagoda, J. E. Starrett Jr,V. K. Gribkoff, P. Hewawasam, N. Srinivas, D. Salazar,W. C. Eckelman, Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener, Nucl. Med. Biol. 2002, 29, 55-59.
59. M. Hugues, D. Duval, P. Kitabgi, M. Lazdunski, J. P. Vincent, Preparation of a pure monoiodo derivative of the bee venom neurotoxin apamin and its binding properties to rat brain synaptosomes, J. Biol. Chem. 1982, 257, 2762-2769.
60. D. J. Anderson, S.P Arneric, Nicotinic receptor binding of [3H]cytisine, [3H]-nicotine and [3H]-methylcarbamylcholine in rat brain, Eur. J. Pharmacol. 1994, 253, 261-267.
61. D. Gnadisch, E. D. London, P. Terry, G. R. Hill, A. G. Mukhin, High affinity binding of [3H]-epibatidine to rat brain membranes, Neuroreport 1999, 10, 1631-1636.
62. H. A. Navarro, D. Zhong, P. Abraham, H. Xu, F. I. Carroll, Synthesis and pharmacological characterization of [125I]-iodomethyllycaconitine ([125I]-iodo-MLA). A new ligand for the alpha 7 nicotinic acetylcholine receptor, J. Med. Chem. 2000, 43, 142-145.
63. H. R. Arias, J. R. Trudell, E. Z. Bayer, B. Hester, E. A. McCardy, M. P. Blanton, Noncompetitive antagonist binding sites in the torpedo nicotinic acetylcholine receptor ion channel. Structureactivity relationship studies using adamantane derivatives, Biochemistry 2003, 42, 7358-7370.
64. F. Murray, J. Kennedy, P. H. Hutson, J. Elliot, I. Huscroft, K. Mohnen, M. G. Russell, S. Grimwood, Modulation of [3H]-MK-801 binding to NMDA receptors in vivo and in vitro, Eur. J. Pharmacol. 2000, 397, 263-270.
65. L. Bunch,T. H. Johansen, H. Brauner-Osborne,T. B. Stensbol,T. N. Johansen, P. Krogsgaard-Larsen, U. Madsen, Synthesis and receptor 186 7 Ion Flux and Ligand Binding Assays for Analysis of Ion Channels binding affinity of new selective GluR5 ligands, Bioorg. Med. Chem. 2001, 9, 875-879.
66. A. M. Linden, H. Yu, H. Zarrinmayeh, W. J. Wheeler, P. Skolnick, Binding of an AMPA receptor potentiator ([3H]-LY395153) to native and recombinant AMPA receptors, Neuropharmacology 2001, 40, 1010-1018.
67. V. Mutel, et al., Binding characteristics of a potent AMPA receptor antagonist [3H]Ro 48-8587 in rat brain, J. Neurochem. 1998, 71, 418-426.
68. N. Crawford,T. K. Lang, D. S. Kerr, D. J. de Vries, High-affinity [3H] kainic acid binding to brain membranes: a reevaluation of ligand potency and selectivity, J. Pharmacol. Toxicol. Methods 1999, 42, 121-125.
69. K. K. Dev,V. Petersen,T. Honore, J. M. Henley, Pharmacology and regional distribution of the binding of 6-[3H]-nitro-7-sulphamoylbenzo[ f ]-quinoxaline-2,3-dione to rat brain, J. Neurochem. 1996, 67, 2609-2612.
70. L. H. Martini, C. R. Souza, P. B. Marques, J. B. Calixto, R. A. Yunes, D. O. Souza, Compounds extracted from Phyllantus and Jatropha elliptica inhibit the binding of [3H]-glutamate and [3H]-GMP-PNP in rat cerebral cortex membrane, Neurochem. Res. 2000, 25, 211-215.
71. R. H. Porter, R. S. Briggs, P. J. Roberts, Modulation of [3H]3-((+-)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid ([3H]CPP) binding by ligands acting at the glycine and the polyamine sites of the rat brain NMDA receptor complex, Eur. J. Pharmacol. 1992, 227, 83-88.
72. J. J. Rauh, et al., Effects of [3H]-BIDN, a novel bicyclic dinitrile radioligand for GABA-gated chloride channels of insects and vertebrates, Br. J. Pharmacol. 1997, 121, 1496-1505.
73. S. K. Sullivan, R. E. Petroski, G. Verge, R. S. Gross, A. C. Foster, D. E. Grigoriadis, Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor, J. Pharmacol. Exp. Ther. 2004, 311, 537-546.
74. S. C. Lummis, J. Baker, Radioligand binding and photoaffinity labelling studies show a direct interaction of phenothiazines at 5-HT3 receptors, Neuropharmacology 1997, 36, 665-70.
75. R. J. Vandenberg, C. R. French, P. H. Barry, J. Shine, P. R. Schofield, Antagonism of ligand-gated ion channel receptors: two domains of the glycine receptor alpha subunit form the strychnine-binding site, Proc. Natl. Acad. Sci. USA. 1992, 89, 1765-1769.